{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:33:31Z","timestamp":1789774411224,"version":"4.0.1"},"reference-count":38,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2018.0646","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T10:06:40Z","timestamp":1537438000000},"source":"Crossref","is-referenced-by-count":64,"title":["The Diagnosis and Treatment of Penile Cancer"],"prefix":"10.3238","author":[{"given":"Oliver Walther","family":"Hakenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree Louise","family":"Dr\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Erbersdobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten Maik","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Peter","family":"J\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Protzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2018,9,28]]},"reference":[{"key":"10.3238\/arztebl.2018.0646_ref1","doi-asserted-by":"crossref","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C: TNM classification of malignant tumours. Union for International Cancer Control; Oxford: John Wiley & Sons 2017.","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"key":"10.3238\/arztebl.2018.0646_ref2","doi-asserted-by":"crossref","unstructured":"Erbersdobler A: [Pathology and histopathological evaluation of penile cancer]. Urologe 2018; 57: 391\u20137","DOI":"10.1007\/s00120-018-0592-8"},{"key":"10.3238\/arztebl.2018.0646_ref3","unstructured":"Robert Koch-Institut und Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V: Krebs in Deutschland f\u00fcr 2013\/2014. Berlin 2017. www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/kid_2017\/krebs_in_deutschland_2017.pdf?__blob=publicationFile (last accessed on 8 August 2018)."},{"key":"10.3238\/arztebl.2018.0646_ref4","doi-asserted-by":"crossref","unstructured":"de Martel C, Plummer M, Vignat J, et al.: Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 2017, 141: 664\u201370","DOI":"10.1002\/ijc.30716"},{"key":"10.3238\/arztebl.2018.0646_ref5","doi-asserted-by":"crossref","unstructured":"Attalla K, Paulucci DJ, Blum K, et al.: Demographic and socioeconomic predictors of treatment delays, pathologic stage, and survival among patients with penile cancer: a report from the national cancer database. Urol Oncol 2018; 36: 14 e17\u201314, e24.","DOI":"10.1016\/j.urolonc.2017.09.014"},{"key":"10.3238\/arztebl.2018.0646_ref6","doi-asserted-by":"crossref","unstructured":"Verhoeven RH, Janssen-Heijnen ML, Saum KU, et al.: Population-based survival of penile cancer patients in Europe and the United States of America: no improvement since 1990. Eur J Cancer 2013; 49: 1414\u201321","DOI":"10.1016\/j.ejca.2012.10.029"},{"key":"10.3238\/arztebl.2018.0646_ref7","doi-asserted-by":"crossref","unstructured":"Comp\u00e9rat E: Pathology of penile cancer. Eur Urol Suppl 2018; 17: 132\u20137","DOI":"10.1016\/j.eursup.2017.08.005"},{"key":"10.3238\/arztebl.2018.0646_ref8","doi-asserted-by":"crossref","unstructured":"Kakies C, Lopez-Beltran A, Comperat E, et al.: Reproducibility of histopathologic tumor grading in penile cancer-results of a European project. Virchows Arch 2014; 464: 453\u201361","DOI":"10.1007\/s00428-014-1548-z"},{"key":"10.3238\/arztebl.2018.0646_ref9","doi-asserted-by":"crossref","unstructured":"Hakenberg OW, Comperat EM, Minhas S, et al.: EAU guidelines on penile cancer: 2014 update. Eur Urol 2015; 67: 142\u201350","DOI":"10.1016\/j.eururo.2014.10.017"},{"key":"10.3238\/arztebl.2018.0646_ref10","doi-asserted-by":"crossref","unstructured":"van Poppel H, Watkin NA, Osanto S, et al.: Penile cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; (Suppl 6): 115\u201324","DOI":"10.1093\/annonc\/mdt286"},{"key":"10.3238\/arztebl.2018.0646_ref11","doi-asserted-by":"crossref","unstructured":"Clark PE, Spiess PE, Agarwal N, et al.: Penile cancer: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2013; 11: 594\u2013615","DOI":"10.6004\/jnccn.2013.0195"},{"key":"10.3238\/arztebl.2018.0646_ref12","doi-asserted-by":"crossref","unstructured":"Jakobsen JK, Jensen JB: DaPeCa-2: implementation of fast-track clinical pathways for penile cancer shortens waiting time and accelerates the diagnostic process\u2014a comparative before-and-after study in a tertiary referral centre in Denmark. Scand J Urol 2016; 50: 80\u20137","DOI":"10.3109\/21681805.2015.1077472"},{"key":"10.3238\/arztebl.2018.0646_ref13","doi-asserted-by":"crossref","unstructured":"Kirrander P, Sherif A, Friedrich B, et al.: Swedish National Penile Cancer Register: incidence, tumour characteristics, management and survival. BJU Int 2016; 117: 287\u201392","DOI":"10.1111\/bju.12993"},{"key":"10.3238\/arztebl.2018.0646_ref14","doi-asserted-by":"crossref","unstructured":"Manjunath A, Brenton T, Wylie S, et al.: Topical therapy for non-invasive penile cancer (Tis)-updated results and toxicity. Transl Androl Urol 2017; 6: 803\u20138","DOI":"10.21037\/tau.2017.06.24"},{"key":"10.3238\/arztebl.2018.0646_ref15","doi-asserted-by":"crossref","unstructured":"Shabbir M, Muneer A, Kalsi J, et al.: Glans resurfacing for the treatment of carcinoma in situ of the penis: surgical technique and outcomes. Eur Urol 2011; 59: 142\u20137","DOI":"10.1016\/j.eururo.2010.09.039"},{"key":"10.3238\/arztebl.2018.0646_ref16","doi-asserted-by":"crossref","unstructured":"Imamura M, MacLennan S, Lam TBL, et al.: Surgical management for localised penile cancer. Cochrane Database Syst Rev 2015; 3: CD011533.","DOI":"10.1002\/14651858.CD011533"},{"key":"10.3238\/arztebl.2018.0646_ref17","doi-asserted-by":"crossref","unstructured":"Chipollini J, Yan S, Ottenhof SR, et al.: Surgical management of penile carcinoma in situ: results from an international collaborative study and review of the literature. BJU Int 2018; 121: 393\u20138","DOI":"10.1111\/bju.14037"},{"key":"10.3238\/arztebl.2018.0646_ref18","doi-asserted-by":"crossref","unstructured":"Tang DH, Yan S, Ottenhof SR, et al.: Glansectomy as primary management of penile squamous cell carcinoma: an international study collaboration. Urology 2017; 109: 1040\u20133","DOI":"10.1016\/j.urology.2017.08.004"},{"key":"10.3238\/arztebl.2018.0646_ref19","doi-asserted-by":"crossref","unstructured":"Minhas S, Kayes O, Hegarty P, et al.: What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int 2005; 96: 1040\u20133","DOI":"10.1111\/j.1464-410X.2005.05769.x"},{"key":"10.3238\/arztebl.2018.0646_ref20","doi-asserted-by":"crossref","unstructured":"Leijte JA, Kirrander P, Antonini N, et al.: Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 2008; 54: 161\u20138","DOI":"10.1016\/j.eururo.2008.04.016"},{"key":"10.3238\/arztebl.2018.0646_ref21","doi-asserted-by":"crossref","unstructured":"Zouhair A, Coucke PA, Jeanneret W, et al.: Radiation therapy alone or combined surgery and radiation therapy in squamous-cell carcinoma of the penis? Eur J Cancer 2001; 37: 198\u2013203","DOI":"10.1016\/S0959-8049(00)00368-3"},{"key":"10.3238\/arztebl.2018.0646_ref22","doi-asserted-by":"crossref","unstructured":"Crook J, Ma C, Grimard L: Radiation therapy in the management of the primary penile tumor: an update. World J Urol 2009; 27: 189\u201396","DOI":"10.1007\/s00345-008-0309-5"},{"key":"10.3238\/arztebl.2018.0646_ref23","doi-asserted-by":"crossref","unstructured":"Li J, Zhu Y, Zhang SL, et al.: Organ-sparing surgery for penile cancer: complications and outcomes. Urology 2011; 78: 1121\u20134","DOI":"10.1016\/j.urology.2011.08.006"},{"key":"10.3238\/arztebl.2018.0646_ref24","doi-asserted-by":"crossref","unstructured":"Crook J, Grimard L, Pond G, et al.: Penile brachytherapy: results for 60 patients. Urology 2007; 70: 161\u20135","DOI":"10.1016\/j.urology.2007.06.121"},{"key":"10.3238\/arztebl.2018.0646_ref25","doi-asserted-by":"crossref","unstructured":"Escande A, Haie-Meder C, Mazeron R, et al.: Brachytherapy for conservative treatment of invasive penile carcinoma: prognostic factors and long-term analysis of outcome. Int J Radiat Oncol Biol Phys 2017; 99: 563\u201370","DOI":"10.1016\/j.ijrobp.2017.02.090"},{"key":"10.3238\/arztebl.2018.0646_ref26","doi-asserted-by":"crossref","unstructured":"Persson B, Sj\u00f6din JG, Holmberg L, et al.: The national penile cancer register in Sweden 2000\u20132003. Scand J Urol Nephrol 2007; 41: 278\u201382","DOI":"10.1080\/00365590601183709"},{"key":"10.3238\/arztebl.2018.0646_ref27","doi-asserted-by":"crossref","unstructured":"O\u2018Brien JS, Perera M, Manning T, et al.: Penile cancer: contemporary lymph node management. J Urol 2017; 197: 1387\u201395","DOI":"10.1016\/j.juro.2017.01.059"},{"key":"10.3238\/arztebl.2018.0646_ref28","doi-asserted-by":"crossref","unstructured":"Zou ZJ, Liu ZH, Tang LY, et al.: Radiocolloid-based dynamic sentinel lymph node biopsy in penile cancer with clinically negative inguinal lymph node: an updated systematic review and meta-analysis. Int Urol Nephrol 2016; 48: 2001\u201313","DOI":"10.1007\/s11255-016-1405-x"},{"key":"10.3238\/arztebl.2018.0646_ref29","doi-asserted-by":"crossref","unstructured":"Necchi A, Pond GR, Raggi D, et al.: Clinical outcomes of perioperative chemotherapy in patients with locally advanced penile squamous-cell carcinoma: results of a multicenter analysis. Clin Genitourin Cancer 2017; 15: 548\u201355","DOI":"10.1016\/j.clgc.2017.02.002"},{"key":"10.3238\/arztebl.2018.0646_ref30","doi-asserted-by":"crossref","unstructured":"Necchi A, Lo Vullo S, Nicolai N, et al.: Prognostic factors of adjuvant taxane, cisplatin, and 5-fluorouracil chemotherapy for patients with penile squamous cell carcinoma after regional lymphadenectomy. Clin Genitourin Cancer 2016; 14: 518\u201323","DOI":"10.1016\/j.clgc.2016.03.005"},{"key":"10.3238\/arztebl.2018.0646_ref31","doi-asserted-by":"crossref","unstructured":"Nicolai N, Sangalli LM, Necchi A, et al.: A combination of cisplatin and 5-fluorouracil with a taxane in patients who underwent lymph node dissection for nodal metastases from squamous cell carcinoma of the penis: treatment outcome and survival analyses in neoadjuvant and adjuvant settings. Clin Genitourin Cancer 2016; 14: 323\u201330","DOI":"10.1016\/j.clgc.2015.07.009"},{"key":"10.3238\/arztebl.2018.0646_ref32","doi-asserted-by":"crossref","unstructured":"Dickstein RJ, Munsell MF, Pagliaro LC, et al.: Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy. BJU Int 2016; 117: 118\u201325","DOI":"10.1111\/bju.12946"},{"key":"10.3238\/arztebl.2018.0646_ref33","doi-asserted-by":"crossref","unstructured":"Hakenberg OW, Nippgen JB, Froehner M, et al.: Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int 2006; 98: 1225\u20137","DOI":"10.1111\/j.1464-410X.2006.06496.x"},{"key":"10.3238\/arztebl.2018.0646_ref34","doi-asserted-by":"crossref","unstructured":"Pizzocaro G, Nicolai N, Milani A: Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol 2009; 55: 546\u201351","DOI":"10.1016\/j.eururo.2008.07.014"},{"key":"10.3238\/arztebl.2018.0646_ref35","doi-asserted-by":"crossref","unstructured":"Pizzocaro G, Piva L: Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 1988; 27: 823\u20134","DOI":"10.3109\/02841868809094366"},{"key":"10.3238\/arztebl.2018.0646_ref36","doi-asserted-by":"crossref","unstructured":"Pagliaro LC, Williams DL, Daliani D, et al.: Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010; 28: 3851\u20137","DOI":"10.1200\/JCO.2010.29.5477"},{"key":"10.3238\/arztebl.2018.0646_ref37","doi-asserted-by":"crossref","unstructured":"Djajadiningrat RS, Graafland NM, van Werkhoven E, et al.: Contemporary management of regional nodes in penile cancer-improvement of survival? J Urol 2014; 191: 68\u201373","DOI":"10.1016\/j.juro.2013.07.088"},{"key":"10.3238\/arztebl.2018.0646_ref38","doi-asserted-by":"crossref","unstructured":"Necchi A, Lo Vullo S, Perrone F, et al.: First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. BJU Int 2018; 121: 348\u201356 CrossRef","DOI":"10.1111\/bju.14013"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T14:01:46Z","timestamp":1638799306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,28]]},"references-count":38,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2018.0646","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,28]]}}}